BCM
AXSM icon

Boxer Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Boxer Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-470,000
Closed -$39.8M – 31
2024
Q4 		$39.8M Buy
+470,000
New +$43.2M 3.39% 7

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Boxer Capital Management's AXSM Position: Q1 2025 in Review

Boxer Capital Management sold out of Axsome Therapeutics (AXSM) in Q1 2025, closing a stake of 470,000 shares — an estimated $39.8M sold.

Boxer Capital Management first reported a position in AXSM in Q4 2024 and held it in 1 quarter. The position peaked at $39.8M in Q4 2024. 353 funds tracked by Wall St. Rank hold AXSM as of Q1 2025.

  • Boxer Capital Management reported no remaining Axsome Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Boxer Capital Management sold 470,000 Axsome Therapeutics shares in Q1 2025, an estimated $39.8M.
  • Boxer Capital Management first reported a position in Axsome Therapeutics in Q4 2024 and held it in 1 quarter.
  • Boxer Capital Management's Axsome Therapeutics position peaked at $39.8M in Q4 2024.
  • 353 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2025.

Based on Boxer Capital Management's 13F filing for Q1 2025, filed 15 May 2025.